Can I read Imbruvica: Mechanism and Efficacy Overview on EtoBox?

Imbruvica: Mechanism and Efficacy Overview by Diti Shah is a document available to read on EtoBox.

What is Imbruvica: Mechanism and Efficacy Overview about?

Imbruvica is a BTK inhibitor approved for treating chronic lymphocytic leukemia and small lymphocytic lymphoma. It is dosed orally once daily at 420 mg. Clinical trials showed Imbruvica monotherapy and in combination with rituximab improved progression-free survival and overall survival compared to other treatments in untreated CLL patients. Common adverse events included diarrhea, fatigue, bleeding events, and atrial fibrillation. Warnings and precautions include hemorrhage, infections, cytopenias, hyperte

Author

Diti Shah

Language

EN